Sebti S, Hamilton A D
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612-9497, USA.
Curr Opin Oncol. 1997 Nov;9(6):557-61. doi: 10.1097/00001622-199711000-00011.
Because farnesylation of Ras is required for its cancer-causing activity, several classes of farnesyl transferase inhibitors have recently been developed as potential anticancer drugs. During the last 12 months, important advances have been made in this field. In this review, we focus on three topics: targets of farnesyl transferase inhibitors other than Ras, alternative prenylation of K-Ras by the closely related prenyl transferase, geranyl geranyl transferase I, and the effects of geranyl geranyl transferase I inhibitors on cell cycle, apoptosis, and human tumor growth.
由于Ras的法尼基化是其致癌活性所必需的，最近已开发出几类法尼基转移酶抑制剂作为潜在的抗癌药物。在过去12个月中，该领域取得了重要进展。在本综述中，我们关注三个主题：Ras以外的法尼基转移酶抑制剂的靶点、密切相关的异戊二烯基转移酶香叶基香叶基转移酶I对K-Ras的替代异戊二烯化，以及香叶基香叶基转移酶I抑制剂对细胞周期、细胞凋亡和人类肿瘤生长的影响。
